Kazano

Physical Activity, Type 2 Diabetes, Diet

Treatment

4 FDA approvals

20 Active Studies for Kazano

What is Kazano

Alogliptin

The Generic name of this drug

Treatment Summary

Alogliptin is an oral medication used to block the activity of an enzyme called dipeptidyl peptidase-4 (DPP-4). It is available as a salt and is mostly made up of the R-enantiomer form. Alogliptin was approved by the FDA in 2013.

Nesina

is the brand name

image of different drug pills on a surface

Kazano Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Nesina

Alogliptin

2013

26

Approved as Treatment by the FDA

Alogliptin, also known as Nesina, is approved by the FDA for 4 uses which include Type 2 Diabetes Mellitus and Physical Activity .

Type 2 Diabetes Mellitus

Used to treat Type 2 Diabetes Mellitus in combination with Pioglitazone

Physical Activity

Used to treat Exercise in combination with Pioglitazone

Type 2 Diabetes

Used to treat Type 2 Diabetes Mellitus in combination with Pioglitazone

Diet

Used to treat Diet in combination with Pioglitazone

Effectiveness

How Kazano Affects Patients

Alogliptin is effective within 2-3 hours of taking a single dose, and can keep working for up to 24 hours if taken in a dose of 25 mg or higher. It reduces the amount of glucagon produced after eating, and increases the amount of active GLP-1 in the body. Alogliptin does not have any effect on the heart's electrical activity.

How Kazano works in the body

Alogliptin helps control blood sugar levels by blocking an enzyme that breaks down two hormones that regulate blood sugar. These hormones, called incretins, stimulate the pancreas to produce insulin and suppress the production of glucagon. They also make you feel full and reduce the amount of food you eat. Blocking the enzyme that breaks them down allows more of these hormones to remain active, helping to control your blood sugar.

When to interrupt dosage

The prescribed dosage of Kazano is contingent upon the specified condition, including Diet, Physical Activity and Type 2 Diabetes. The magnitude of dosage is based on the technique of administration indicated in the table below.

Condition

Dosage

Administration

Diet

, 6.25 mg, 12.5 mg, 25.0 mg

, Tablet - Oral, Oral, Tablet, Tablet, film coated, Tablet, film coated - Oral

Type 2 Diabetes

, 6.25 mg, 12.5 mg, 25.0 mg

, Tablet - Oral, Oral, Tablet, Tablet, film coated, Tablet, film coated - Oral

Physical Activity

, 6.25 mg, 12.5 mg, 25.0 mg

, Tablet - Oral, Oral, Tablet, Tablet, film coated, Tablet, film coated - Oral

Warnings

There are 20 known major drug interactions with Kazano.

Common Kazano Drug Interactions

Drug Name

Risk Level

Description

Amitriptyline

Major

The metabolism of Amitriptyline can be decreased when combined with Alogliptin.

Amoxapine

Major

The metabolism of Amoxapine can be decreased when combined with Alogliptin.

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Alogliptin.

Clomipramine

Major

The metabolism of Clomipramine can be decreased when combined with Alogliptin.

Clonidine

Major

The metabolism of Clonidine can be decreased when combined with Alogliptin.

Kazano Toxicity & Overdose Risk

Common side effects of alogliptin include a stuffy or runny nose, headaches, and a cold or other upper respiratory infection.

image of a doctor in a lab doing drug, clinical research

Kazano Novel Uses: Which Conditions Have a Clinical Trial Featuring Kazano?

196 active clinical trials are investigating the utility of Kazano in augmenting Physical Activity, ameliorating Type 2 Diabetes and optimizing Diet.

Condition

Clinical Trials

Trial Phases

Diet

4 Actively Recruiting

Not Applicable, Phase 1

Physical Activity

25 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Type 2 Diabetes

162 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1

Kazano Reviews: What are patients saying about Kazano?

5

Patient Review

4/6/2021

Kazano for Type 2 Diabetes Mellitus

I don't know why, but metformin alone makes my stomach unbearably upset. With Kazano my blood sugar levels are great and I have no GI issues.

3.7

Patient Review

9/5/2013

Kazano for Type 2 Diabetes Mellitus

3.7

Patient Review

12/19/2013

Kazano for Type 2 Diabetes Mellitus

3.3

Patient Review

5/18/2016

Kazano for Type 2 Diabetes Mellitus

For the past two years, this medication has been great for keeping my A1c levels down. However, I've recently noticed that my blood sugar is always high, especially in the morning. Nothing else in my routine has changed, so I think it might be time to switch medications.

3.3

Patient Review

2/28/2014

Kazano for Type 2 Diabetes Mellitus

I was really sweating a lot, my eyes were watery, and I had a runny nose.

3

Patient Review

9/29/2014

Kazano for Type 2 Diabetes Mellitus

Unfortunately, I experienced some pretty intense diarrhea. This also came with nausea and a loss of appetite.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about kazano

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of Kazano?

"An upper respiratory tract infection can cause symptoms like a stuffy nose, sinus pain, and a sore throat. Other possible causes of these symptoms include a cold, a headache, back pain, a urinary tract infection, high blood pressure, and diarrhea."

Answered by AI

What is Kazano used for?

"Kazano is a combination medication containing alogliptin and metformin. This medication is designed to be used in conjunction with diet and exercise to improve blood sugar control in people with type 2 diabetes."

Answered by AI

How much does Kazano cost?

"The price of Kazano oral tablets (12.5 mg-500 mg) varies depending on the pharmacy, but is around $440 for a supply of 60 tablets. This price is for cash paying customers only and does not apply to customers with insurance plans."

Answered by AI

What are Gliflozin drugs?

"This class of drugs is used to lower high blood glucose levels in people with type 2 diabetes by inhibiting the SGLT-2 proteins located in the renal tubules of the kidneys, which are responsible for reabsorbing glucose back into the blood."

Answered by AI

Clinical Trials for Kazano

Image of NYU Langone Health in New York, United States.

Adaptive Dietary Intervention for Type 2 Diabetes

18+
All Sexes
New York, NY

The investigators will examine the feasibility, acceptability, and effect of an adaptive dietary intervention over 24 weeks (12-week intervention, 12-week follow-up) among Asian Americans with Type 2 diabetes. Participants (N=120; 60 Chinese Americans and 60 Vietnamese Americans) will be 2:1 randomized to one of two arms: adaptive dietary intervention or standard of care (SC). The intervention will begin with continued glucose monitoring (CGM) use only during weeks 0-4. At week 4, participants who achieve the glycemic control goal (at least an 8% increase in time in range \[TIR\] from baseline) will continue with the CGM alone during weeks 4-12 ("CGM Alone"); otherwise, culturally and linguistically adapted glucose excursion minimization (GEM) will be augmented with CGM ("CGM-GEM").

Waitlist Available
Has No Placebo

NYU Langone Health

Yaguang Zheng, PhD, RN

Have you considered Kazano clinical trials?

We made a collection of clinical trials featuring Kazano, we think they might fit your search criteria.
Go to Trials
Image of KPNC Division of Research in Pleasanton, United States.

MetSense Risk Flag for Type 2 Diabetes

18+
All Sexes
Pleasanton, CA

People with serious mental illness have high risk for type 2 diabetes due to multiple risk factors, including the metabolic side effects of psychotropic medications that are used to treat these conditions. Type 2 diabetes is preventable through lifestyle and pharmacological interventions, but many people with serious mental illness do not receive regular screening for type 2 diabetes risk. In many health care settings, clinical pharmacists are increasingly managing patients with serious mental illness and have expertise in monitoring the metabolic side effects of psychotropic medications. This study evaluates the feasibility and acceptability of using a diabetes prediction model that is based on electronic health record data (the MetSense risk flag) to alert clinical pharmacists about patients who are at high diabetes risk, prompting these clinicians to prioritize diabetes risk management services.

Waitlist Available
Has No Placebo

KPNC Division of Research

Esti Iturralde, PhD

Image of University of California, Los Angeles in Los Angeles, United States.

Tailored DPP for Prediabetes

17 - 25
All Sexes
Los Angeles, CA

The goal of this study is to enhance reach and uptake of diabetes prevention among young adults, with a focus on recruiting underserved and high-need students who face additional challenges, including food and financial insecurity. The specific aims are: Aim 1 - Evaluate the efficacy of an AYA-tailored version of the UC DPP for mitigating type 2 diabetes risk (i.e., weight change) in a pre/post pilot trial. The investigators hypothesize that the AYA-tailored intervention will be effective at producing 5% weight loss from baseline to program completion (at 9-months). Aim 2 - Assess the feasibility and acceptability of an AYA-tailored version of the UC DPP program. The investigators hypothesize that it will be feasible to recruit the desired number of participants given proposed innovative outreach strategies, and that the AYA-tailored intervention will be deemed acceptable to participants both qualitatively and in regards to their retention in the program at rates similar to the larger UC DPP. The investigators will recruit 80 UCLA undergraduate students. Participants will be asked to complete a brief screening online form to assess eligibility and to collect contact information. The PI and/or Research Assistants (RAs) will reach out to eligible participants to obtain informed consent and enroll them in the pilot trial. The investigators will randomize participants to the tailored DPP cohort vs control cohort. Control participants will be offered the opportunity to participate in the tailored DPP in the following academic year. The tailored DPP intervention will be online and asynchronously. Participants will be asked to complete the intervention lessons on their own time. Each lesson typically takes on average 15 minutes to complete. Control group will receive each intervention materials via e-mail for participants to review on their own time and will receive acceptability surveys. The interventions for the control group will be remote. A research assistant will meet with control participants via Zoom to explain the intervention materials. Control group will receive access to a study habits intervention, alcohol use intervention, and financial literacy intervention. At the end of each quarter (Fall, Winter, and Spring), both control and intervention participants will receive an email with a unique link to a brief REDCap survey to ascertain acceptability of sessions/lessons. Furthermore, participants will complete baseline and 9-month follow-up assessments. Participants will complete a 30 minute questionnaire and height/weight measurements will be collected by a RA. Participants will be asked to self-report weight and physical activity at the end of the fall and winter quarter; data will be collected via brief REDCap survey.

Recruiting
Has No Placebo

University of California, Los Angeles

Lauren E Wisk, PhD

Have you considered Kazano clinical trials?

We made a collection of clinical trials featuring Kazano, we think they might fit your search criteria.
Go to Trials
Image of The Worship Center Cristian Church in Birmingham, United States.

Black Impact for Heart Health

18+
Male
Birmingham, AL

The goal of this clinical trial is to evaluate the implementation and effectiveness of the FELLAship program-a church-based cardiovascular health (CVH) intervention-in Black men aged 35-70 who are at risk for heart disease, diabetes, obesity, and related conditions. The main questions this study aims to answer are: * Does participation in the FELLAship program improve cardiovascular health metrics (e.g., blood pressure, cholesterol, blood sugar) and health behaviors among Black men at The Worship Center Christian Church (TWC)? * What factors influence the adoption, delivery, and sustainability of the FELLAship program in a faith-based setting? Researchers will compare an immediate-start intervention group and a delayed-start (waitlist control) group to assess both short-term health outcomes and program implementation factors. Participants will: * Attend a 90-minute weekly session for 24 weeks, including 45 minutes of physical activity led by a certified trainer and 45 minutes of health education delivered by trained coaches. * Receive one-on-one support from a community health worker to reduce barriers to care and engage with primary care. * Complete biometric health screenings and surveys at baseline, 12 weeks, and 24 weeks to assess clinical and behavioral outcomes. * Use a smartwatch, blood pressure cuff, and other tools to track progress in real time. * Participate in exit focus groups or interviews to share feedback about the intervention. * A subset of TWC leaders and interventionists (N=15) will also be interviewed to assess implementation, resource needs, and sustainability. This study uses the RE-AIM framework to assess Reach, Effectiveness, Adoption, Implementation, and Maintenance, and aims to inform scalable strategies for improving CVH among Black men in trusted community settings.

Recruiting
Has No Placebo

The Worship Center Cristian Church

Have you considered Kazano clinical trials?

We made a collection of clinical trials featuring Kazano, we think they might fit your search criteria.
Go to Trials